This report describes and explains the primary ovarian insufficiency market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global primary ovarian insufficiency market reached a value of nearly $1.17 billion in 2025, having grown at a compound annual growth rate (CAGR) of 9.4% since 2020. The market is expected to grow from $1.17 billion in 2025 to $1.81 billion in 2030 at a rate of 9.1%. The market is then expected to grow at a CAGR of 7.5% from 2030 and reach $2.61 billion in 2035.
Growth in the historic period resulted from the rising female infertility rates, increasing prevalence of primary ovarian insufficiency (POI), rising adoption of hormone replacement therapy (HRT) and growing use of genetic screening and testing. Factors that negatively affected growth in the historic period were high cost of hormone and fertility treatments and limited access to specialized reproductive healthcare.
Going forward, the growing healthcare expenditure on women’s health, increasing incidence of lifestyle-related disorders, improved access to specialized women’s healthcare services and expansion of awareness and education campaigns will drive the growth. Factors that could hinder the growth of the primary ovarian insufficiency market in the future include limited awareness and delayed diagnosis lack, of standardized clinical guidelines and impact of trade war and tariff.
The primary ovarian insufficiency market is segmented by type into hormone replacement therapy (HRT), calcium and vitamin D supplements, in vitro fertilization (IVF), stem cell therapy and other types. The hormone replacement therapy (HRT) market was the largest segment of the primary ovarian insufficiency market segmented by type, accounting for 52.9% or $623.5 million of the total in 2025. Going forward, the stem cell therapy segment is expected to be the fastest growing segment in the primary ovarian insufficiency market segmented by type, at a CAGR of 10.6% during 2025-2030.
The primary ovarian insufficiency market is segmented by diagnosis method into blood tests, ultrasound imaging and genetic testing. The blood tests market was the largest segment of the primary ovarian insufficiency market segmented by diagnosis method, accounting for 61.6% or $726 million of the total in 2025. Going forward, the genetic testing segment is expected to be the fastest growing segment in the primary ovarian insufficiency market segmented by diagnosis method, at a CAGR of 11.9% during 2025-2030.
The primary ovarian insufficiency market is segmented by application into less than 20 years old, 20 to 30 years old, 30 to 45 years old and 45 years old and older. The 30 to 45 years old market was the largest segment of the primary ovarian insufficiency market segmented by application, accounting for 55.1% or $649.4 million of the total in 2025. Going forward, the 30 to 45 years old segment is expected to be the fastest growing segment in the primary ovarian insufficiency market segmented by application, at a CAGR of 10.1% during 2025-2030.
The primary ovarian insufficiency market is segmented by end-user into hospitals and clinics and specialty fertility centers. The hospitals and clinics market was the largest segment of the primary ovarian insufficiency market segmented by end user, accounting for 74.6% or $878.8 million of the total in 2025. Going forward, the specialty fertility centers segment is expected to be the fastest growing segment in the primary ovarian insufficiency market segmented by end user, at a CAGR of 10.3% during 2025-2030.
North America was the largest region in the primary ovarian insufficiency market, accounting for 34.1% or $401.2 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the primary ovarian insufficiency market will be Asia Pacific and Western Europe where growth will be at CAGRs of 10.8% and 10.4% respectively. These will be followed by Africa and South America where the markets are expected to grow at CAGRs of 9.5% and 9.2% respectively.
The global primary ovarian insufficiency market is fairly fragmented, with a large number of small players operating in the market. The top ten competitors in the market made up to 21.1% of the total market in 2024. Mayo Clinic was the largest competitor with a 3.9% share of the market, followed by Johns Hopkins Medicine with 3.6%, Cleveland Clinic with 3.2%, Royan Institute with 2.4%, Progyny Inc with 2%, Baptist Health with 1.9%, Pristyn Care with 1.3%, CCRM Fertility with 1.1%, Kindbody with 0.9% and Shady Grove Fertility with 0.7%.
The top opportunities in the primary ovarian insufficiency market segmented by type will arise in the hormone replacement therapy (HRT) segment, which will gain $341.7 million of global annual sales by 2030. The top opportunities in the primary ovarian insufficiency market segmented by diagnosis method will arise in the blood tests segment, which will gain $362.5 million of global annual sales by 2030. The top opportunities in the primary ovarian insufficiency market segmented by application will arise in the 30 to 45 years old segment, which will gain $402.3 million of global annual sales by 2030. The top opportunities in the primary ovarian insufficiency market segmented by end-user will arise in the hospitals and clinics segment, which will gain $452.1 million of global annual sales by 2030. The primary ovarian insufficiency market size will gain the most in the USA at $139.8 million.
Market-trend-based strategies for the primary ovarian insufficiency market include focus on advancement of AI-enabled embryo selection platforms to improve IVF outcomes, focus on development of cell-free regenerative therapies to restore ovarian function, focus on adoption of high-precision embryo incubation systems, focus on advancement of precision diagnostic biomarkers for early identification, focus on advancement of cell-free regenerative therapeutics to restore ovarian function and focus on expansion of at-home fertility diagnostic kits to enable early ovarian reserve screening.
Player-adopted strategies in the primary ovarian insufficiency market include focus on expanding business capabilities through strategic partnerships.
To take advantage of the opportunities, the analyst recommends the primary ovarian insufficiency companies to focus on leveraging AI-driven embryo selection to improve IVF outcomes, focus on expanding regenerative therapies for POI patients, focus on implementing high-precision embryo incubation systems, focus on advancing diagnostic biomarkers for early POI detection, focus on expanding cell-free regenerative therapies for POI, focus on expanding at-home fertility diagnostics, focus on investing in stem cell therapy for POI, focus on expanding genetic testing for early and precise POI diagnosis, focus on expanding multichannel distribution networks, focus on implementing tiered and value-based pricing strategies, focus on building clinical awareness and patient education, focus on enhancing engagement through targeted outreach and support programs, focus on targeting women aged 30 to 45 years for POI services, focus on expanding specialty fertility centers for POI care.
This product will be delivered within 3-5 business days.
The global primary ovarian insufficiency market reached a value of nearly $1.17 billion in 2025, having grown at a compound annual growth rate (CAGR) of 9.4% since 2020. The market is expected to grow from $1.17 billion in 2025 to $1.81 billion in 2030 at a rate of 9.1%. The market is then expected to grow at a CAGR of 7.5% from 2030 and reach $2.61 billion in 2035.
Growth in the historic period resulted from the rising female infertility rates, increasing prevalence of primary ovarian insufficiency (POI), rising adoption of hormone replacement therapy (HRT) and growing use of genetic screening and testing. Factors that negatively affected growth in the historic period were high cost of hormone and fertility treatments and limited access to specialized reproductive healthcare.
Going forward, the growing healthcare expenditure on women’s health, increasing incidence of lifestyle-related disorders, improved access to specialized women’s healthcare services and expansion of awareness and education campaigns will drive the growth. Factors that could hinder the growth of the primary ovarian insufficiency market in the future include limited awareness and delayed diagnosis lack, of standardized clinical guidelines and impact of trade war and tariff.
The primary ovarian insufficiency market is segmented by type into hormone replacement therapy (HRT), calcium and vitamin D supplements, in vitro fertilization (IVF), stem cell therapy and other types. The hormone replacement therapy (HRT) market was the largest segment of the primary ovarian insufficiency market segmented by type, accounting for 52.9% or $623.5 million of the total in 2025. Going forward, the stem cell therapy segment is expected to be the fastest growing segment in the primary ovarian insufficiency market segmented by type, at a CAGR of 10.6% during 2025-2030.
The primary ovarian insufficiency market is segmented by diagnosis method into blood tests, ultrasound imaging and genetic testing. The blood tests market was the largest segment of the primary ovarian insufficiency market segmented by diagnosis method, accounting for 61.6% or $726 million of the total in 2025. Going forward, the genetic testing segment is expected to be the fastest growing segment in the primary ovarian insufficiency market segmented by diagnosis method, at a CAGR of 11.9% during 2025-2030.
The primary ovarian insufficiency market is segmented by application into less than 20 years old, 20 to 30 years old, 30 to 45 years old and 45 years old and older. The 30 to 45 years old market was the largest segment of the primary ovarian insufficiency market segmented by application, accounting for 55.1% or $649.4 million of the total in 2025. Going forward, the 30 to 45 years old segment is expected to be the fastest growing segment in the primary ovarian insufficiency market segmented by application, at a CAGR of 10.1% during 2025-2030.
The primary ovarian insufficiency market is segmented by end-user into hospitals and clinics and specialty fertility centers. The hospitals and clinics market was the largest segment of the primary ovarian insufficiency market segmented by end user, accounting for 74.6% or $878.8 million of the total in 2025. Going forward, the specialty fertility centers segment is expected to be the fastest growing segment in the primary ovarian insufficiency market segmented by end user, at a CAGR of 10.3% during 2025-2030.
North America was the largest region in the primary ovarian insufficiency market, accounting for 34.1% or $401.2 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the primary ovarian insufficiency market will be Asia Pacific and Western Europe where growth will be at CAGRs of 10.8% and 10.4% respectively. These will be followed by Africa and South America where the markets are expected to grow at CAGRs of 9.5% and 9.2% respectively.
The global primary ovarian insufficiency market is fairly fragmented, with a large number of small players operating in the market. The top ten competitors in the market made up to 21.1% of the total market in 2024. Mayo Clinic was the largest competitor with a 3.9% share of the market, followed by Johns Hopkins Medicine with 3.6%, Cleveland Clinic with 3.2%, Royan Institute with 2.4%, Progyny Inc with 2%, Baptist Health with 1.9%, Pristyn Care with 1.3%, CCRM Fertility with 1.1%, Kindbody with 0.9% and Shady Grove Fertility with 0.7%.
The top opportunities in the primary ovarian insufficiency market segmented by type will arise in the hormone replacement therapy (HRT) segment, which will gain $341.7 million of global annual sales by 2030. The top opportunities in the primary ovarian insufficiency market segmented by diagnosis method will arise in the blood tests segment, which will gain $362.5 million of global annual sales by 2030. The top opportunities in the primary ovarian insufficiency market segmented by application will arise in the 30 to 45 years old segment, which will gain $402.3 million of global annual sales by 2030. The top opportunities in the primary ovarian insufficiency market segmented by end-user will arise in the hospitals and clinics segment, which will gain $452.1 million of global annual sales by 2030. The primary ovarian insufficiency market size will gain the most in the USA at $139.8 million.
Market-trend-based strategies for the primary ovarian insufficiency market include focus on advancement of AI-enabled embryo selection platforms to improve IVF outcomes, focus on development of cell-free regenerative therapies to restore ovarian function, focus on adoption of high-precision embryo incubation systems, focus on advancement of precision diagnostic biomarkers for early identification, focus on advancement of cell-free regenerative therapeutics to restore ovarian function and focus on expansion of at-home fertility diagnostic kits to enable early ovarian reserve screening.
Player-adopted strategies in the primary ovarian insufficiency market include focus on expanding business capabilities through strategic partnerships.
To take advantage of the opportunities, the analyst recommends the primary ovarian insufficiency companies to focus on leveraging AI-driven embryo selection to improve IVF outcomes, focus on expanding regenerative therapies for POI patients, focus on implementing high-precision embryo incubation systems, focus on advancing diagnostic biomarkers for early POI detection, focus on expanding cell-free regenerative therapies for POI, focus on expanding at-home fertility diagnostics, focus on investing in stem cell therapy for POI, focus on expanding genetic testing for early and precise POI diagnosis, focus on expanding multichannel distribution networks, focus on implementing tiered and value-based pricing strategies, focus on building clinical awareness and patient education, focus on enhancing engagement through targeted outreach and support programs, focus on targeting women aged 30 to 45 years for POI services, focus on expanding specialty fertility centers for POI care.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Global Primary Ovarian Insufficiency Growth Analysis and Strategic Analysis Framework
9 Global Primary Ovarian Insufficiency Market Segmentation
10 Primary Ovarian Insufficiency Market, Regional and Country Analysis
11 Asia-Pacific Market
12 Western Europe Market
13 Eastern Europe Market
14 North America Market
15 South America Market
16 Middle East Market
17 Africa Market
18 Competitive Landscape and Company Profiles
19 Other Major and Innovative Companies
21 Key Mergers and Acquisitions
22 Recent Developments in Primary Ovarian Insufficiency
23 Opportunities and Strategies
24 Primary Ovarian Insufficiency Market, Conclusions and Recommendations
25 Appendix
Executive Summary
Primary Ovarian Insufficiency Global Market Opportunities and Strategies to 2035 provides the strategists; marketers and senior management with the critical information they need to assess the global primary ovarian insufficiency market as it emerges from the COVID-19 shut down.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for primary ovarian insufficiency? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The primary ovarian insufficiency market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider primary ovarian insufficiency market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by diagnosis method, by application and by end users.
- Key Trends Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis and Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Regional and Country Analysis Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by type, by diagnosis method, by application and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2020-2035) market values and growth and market share comparison by region market.
- Regional Market Size and Growth Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking Briefs on the financials comparison between major players in the market.
- Competitive Dashboard Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments Information on recent developments in the market covered in the report.
- Conclusions and Recommendations This section includes recommendations for primary ovarian insufficiency providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Market Opportunities and Strategies Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Appendix This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report
1) By Type: Hormone Replacement Therapy (HRT); Calcium and Vitamin D Supplements; In Vitro Fertilization (IVF); Stem Cell Therapy; Other Types
2) By Diagnosis Method: Blood Tests; Ultrasound Imaging; Genetic Testing
3) By Application: Less Than 20 Years Old; 20 To 30 Years Old; 30 To 45 Years Old; 45 Years Old and Older
4) By End-User: Hospitals and Clinics; Specialty Fertility Centers
Companies Mentioned: Mayo Clinic; Johns Hopkins Medicine; Cleveland Clinic; Royan Institute; Progyny Inc.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; primary ovarian insufficiency indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Mayo Clinic
- Johns Hopkins Medicine
- Cleveland Clinic
- Royan Institute
- Progyny Inc.
- Baptist Health
- Pristyn Care
- CCRM Fertility
- Kindbody
- Shady Grove Fertility
- Birla Fertility & IVF
- Iswarya Fertility Center
- IVIRMA Global
- TCM Healthcare
- Sparsh Diagnostic Centre
- Welling Homeopathy Clinics Pvt. Ltd
- Indira IVF Hospital Private Limited,
- Shree IVF Clinics
- Virtus Health
- Sun Pharmaceutical Industries Ltd
- Monash IVF
- City Fertility
- Genea Fertility
- Queensland Fertility Group
- Nova IVF Fertility
- Cloudnine Fertility
- Bloom IVF
- Fortis Healthcare Limited
- Intas Pharmaceuticals Limited
- NYU Langone Hospitals
- IVFAustralia
- Jinxin Fertility Group Ltd
- Guangzhou KingMed Diagnostics Group Co., Ltd.
- Beijing Perfect Family Hospital
- Kindstar Globalgene Technology, Inc.
- Bloomage BioTechnology Corporation Limited
- Shenzhen GeneoDx Biotechnology Co., Ltd.
- IVF Japan Group
- Keio University Hospital
- Sanno Hospital (Tokyo)
- Oak Clinic Group (Osaka, Tokyo, etc.)
- Sysmex Corporation
- Aska Pharmaceutical Co. Ltd.
- Merck Ltd. Korea
- CHA Fertility Center (CHA Medical Group)
- Maria Fertility Hospital
- Seoul Samsung Medical Center
- GeneMatrix
- MediFuture Inc.
- WellFemme
- Australian Menopause Centre Pty Ltd
- Bayer Vietnam Ltd
- ARMC AEGIS Hospital
- Thomson Fertility
- Goeunbit Women's Clinic
- Seoul OBGYN
- VISEN Pharmaceuticals
- Organon International
- Endoceutics Inc.
- Bayer AG, Effik S.A.
- Theramex
- Gedeon Richter Plc.
- Reig Jofre
- Fertypharm/Health Care (OTC)
- Prague Fertility Centre
- IVF Clinic
- IBSA Poland
- InviMed
- Nadezhda Women’s Health Hospital
- EMC Moscow reproductive clinic
- GENESIS Fertility
- Regina Maria
- MedLife
- PreventionGenetics LLC
- Inception Fertility, LLC
- Cryoport, Inc.
- ReproTech LLC
- The Prelude Network
- INVO Bioscience, Inc
- Quantum Health
- Thermo Fisher Scientific, Inc.
- Merck & Co., Inc.
- Cook Medical Inc.
- Fertility Centers of Illinois
- EMD Serono Inc.
- Carolinas Fertility Institute
- Fertility Focus
- Pinnacle Fertility
- Ovation Fertility
- Ottawa Fertility Clinic
- CARE Fertility
- New Hope Fertility Center
- Cleveland Clinic Fertility Center
- The Fertility Partners (TFP)
- NYU Langone Fertility Center
- Fertility Match
- Bio Fertility Center
- Fertility Center Cancun
- Gameto
- Medavie Blue Cross
- Nova IVF
- Femasys Inc.
- Sinai Health
- Conceivable Life Sciences
- Aché Laboratórios
- Libbs Farmacêutica
- Bayer S.A.
- Elea Phoenix
- Caspian Tamin Pharmaceutical Company
- Royan Institute
- Teva Pharmaceutical Industries Ltd.
- IVF Unit - Sheba Medical Center
- Assuta Medical Centers
- Saudi German Health Group
- Fakih IVF Fertility Center
- Centrum Clinic
- ART Fertility Clinics
- Fakih IVF Fertility Center
- Aspen Pharmacare
- The Nairobi Hospital
- Cleopatra Hospitals Group (CHG)
- Merck (Pty) Ltd South Africa
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 361 |
| Published | May 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 1.17 Billion |
| Forecasted Market Value ( USD | $ 2.61 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 122 |
